TALZENNA Adverse Reactions

(talazoparib)

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions (5.1)]
Myelosuppression [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to single agent TALZENNA in solid tumor clinical studies, including 286 patients enrolled in EMBRACA trial and to TALZENNA 0.5 mg daily in combination with enzalutamide in 511 patients enrolled in the TALAPRO-2 trial that included 197 patients with HRR gene-mutated mCRPC.

gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer

EMBRACA

The safety of TALZENNA as a single agent was evaluated in gBRCAm patients with HER2-negative locally advanced or metastatic breast cancer who had previously received no more than 3 lines of chemotherapy for the treatment of locally advanced/metastatic disease [see Clinical Studies (14.1)]. EMBRACA was a randomized, open-label, multi-center study in which 412 patients received either TALZENNA 1 mg once daily (N=286) or a chemotherapy agent (capecitabine, eribulin, gemcitabine, or vinorelbine) of the healthcare provider's choice (N=126) until disease progression or unacceptable toxicity. The median duration of study treatment was 6.1 months in patients who received TALZENNA and 3.9 months in patients who received chemotherapy.

Serious adverse reactions of TALZENNA occurred in 32% of patients. Serious adverse reactions reported in >2% of patients included anemia (6%) and pyrexia (2%). Fatal adverse reactions occurred in 1% of patients, including cerebral hemorrhage, liver disorder, veno-occlusive liver disease, and worsening neurological symptoms (1 patient each).

Permanent discontinuation due to adverse reactions occurred in 5% of TALZENNA patients. Dosing interruptions due to an adverse reaction of any grade occurred in 65% of patients receiving TALZENNA; dose reductions due to any cause occurred in 53% of TALZENNA patients.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased, fatigue, glucose increased, aspartate aminotransferase increased, alkaline phosphatase increased, alanine aminotransferase increased, calcium decreased, nausea, headache, vomiting, alopecia, diarrhea, and decreased appetite.

Table 5 and Table 6 summarize the most common adverse reactions and laboratory abnormalities, respectively, in patients treated with TALZENNA or chemotherapy in the EMBRACA study.

Table 5. Adverse Reactions* (≥20%) in Patients Receiving TALZENNA in EMBRACA
Adverse ReactionsTALZENNA
N=286 (%)
Chemotherapy
N=126 (%)
Grades 1–4Grade 3Grade 4Grades 1–4Grade 3Grade 4
Abbreviation: N=number of patients.
*
Graded according to NCI CTCAE 4.03.
Includes fatigue and asthenia.

General disorders and administration site conditions

Fatigue

62

3

0

50

5

0

Gastrointestinal disorders

Nausea

49

0.3

0

47

2

0

Vomiting

25

2

0

23

2

0

Diarrhea

22

1

0

26

6

0

Nervous system disorders

Headache

33

2

0

22

1

0

Skin and subcutaneous tissue disorders

Alopecia

25

0

0

28

0

0

Metabolism and nutrition disorders

Decreased appetite

21

0.3

0

22

1

0

Clinically relevant adverse reactions in <20% of patients who received TALZENNA included abdominal pain (19%), dizziness (17%), dysgeusia (10%), dyspepsia (10%), stomatitis (8%), and febrile neutropenia (0.3%).

Table 6. Select Laboratory Abnormalities (≥25%) of Patients in EMBRACA
TALZENNA
N*=286 (%)
Chemotherapy
N*=126 (%)
ParameterGrades 1–4Grade 3Grade 4Grades 1–4Grade 3Grade 4
Abbreviation: N=number of patients.
*
This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.
This number represents non-fasting glucose.

Hemoglobin decreased

90

39

0

77

6

0

Neutrophils decreased

68

17

3

70

21

17

Lymphocytes decreased

76

17

0.7

53

8

0.8

Platelets decreased

55

11

4

29

2

0

Glucose increased

54

2

0

51

2

0

Aspartate aminotransferase Increased

37

2

0

48

3

0

Alkaline phosphatase increased

36

2

0

34

2

0

Alanine aminotransferase increased

33

1

0

37

2

0

Calcium decreased

28

1

0

16

0

0

HRR Gene-mutated mCRPC

The safety of TALZENNA in combination with enzalutamide was evaluated in patients with HRR gene-mutated mCRPC enrolled in TALAPRO-2 [see Clinical Studies (14.2)]. Patients were randomized to receive either TALZENNA 0.5 mg in combination with enzalutamide 160 mg once daily (n=197), or placebo in enzalutamide 160 mg once daily (n=199) until disease progression or unacceptable toxicity. Among patients receiving TALZENNA, 86% were exposed for 6 months or longer, 60% were exposed for greater than one year, and 18% were exposed for greater than two years.

Serious adverse reactions of TALZENNA in combination with enzalutamide occurred in 30% of patients. Serious adverse reactions reported in >2% of patients included anemia (9%) and fracture (3%). Fatal adverse reactions occurred in 1.5% of patients, including pneumonia, COVID infection, and sepsis (1 patient each).

Permanent discontinuation of TALZENNA due to adverse reactions occurred in 10% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in permanent discontinuation of TALZENNA were anemia (4%), fatigue, bone fracture, ischemic heart disease, and spinal cord compression (1% each).

Dosage interruption of TALZENNA due to adverse reactions occurred in 58% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose interruption of TALZENNA were anemia (42%), neutropenia (15%), and platelet count decreased (9%) and fatigue (5%).

Dose reduction of TALZENNA due to adverse reactions occurred in 52% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose reduction of TALZENNA were anemia (43%), neutrophil count decreased (15%), platelet count decreased (6%), and fatigue (4%).

The most common adverse reactions (≥10%), including laboratory abnormalities, in patients who received TALZENNA with enzalutamide were hemoglobin decreased, neutrophils decreased, lymphocytes decreased, fatigue, platelets decreased, calcium decreased, nausea, decreased appetite, sodium decreased, phosphate decreased, fractures, magnesium decreased, dizziness, bilirubin increased, potassium decreased, and dysgeusia.

Table 7 and Table 8 summarize the most common adverse reactions and laboratory abnormalities, respectively, in the TALAPRO-2 study.

Table 7. Adverse Reactions* (≥10%) in Patients Receiving TALZENNA [with a Difference Between Arms of ≥2%] in TALAPRO-2
Abbreviation: N=number of patients.
*
Graded according to NCI CTCAE 4.03.
Includes fatigue and asthenia.
Fractures include multiple similar terms.
§
Includes dizziness, dizziness postural, vertigo.
Includes ageusia, anosmia, dysgeusia.

TALZENNA with Enzalutamide

N=197

Placebo with Enzalutamide

N=199

Grades 1-4

%

Grade 3

%

Grade 4

%

Grades 1-4

%

Grade 3

%

Grade 4

%

Fatigue

49

4

0

40

1

0

Nausea

21

2

0

17

1

0.5

Decreased appetite

20

1

0

14

1

1

Fractures

14

3

0

10

1.5

0

Dizziness§

13

1.5

0

9

1.5

0

Dysgeusia

10

0

0

4.5

0

0

Clinically relevant adverse reactions in <10% of patients who received TALZENNA with enzalutamide included abdominal pain (9%), vomiting (9%), alopecia (7%), dyspepsia (4%), venous thromboembolism (3%) and stomatitis (2%).

Table 8. Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received TALZENNA in TALAPRO-2
Abbreviation: N=number of patients.
*
The denominator used to calculate the rate varied from 198 to 199 in the placebo with enzalutamide arm based on the number of patients with a baseline value and at least one post-treatment value.

Laboratory Abnormality

TALZENNA with Enzalutamide

N=197*

Placebo with Enzalutamide

N=199*

Grades 1‑4

%

Grade 3

%

Grade 4

%

Grades 1‑4

%

Grade 3

%

Grade 4

%

Hemoglobin decreased

79

41

0

34

6

0

Neutrophils decreased

60

18

1

18

0

1

Lymphocytes decreased

58

13

0

36

7

0

Platelets decreased

45

6

3

8

0.5

0

Calcium decreased

25

0

1

11

0

1

Sodium decreased

22

3

0

20

1.5

0

Phosphate decreased

17

3

1

13

2

0

Magnesium decreased

14

0

1

12

0

0.5

Bilirubin increased

11

0.5

0

7

0

0

Potassium decreased

11

0

1

7

1

0.5

Find TALZENNA medical information:

Find TALZENNA medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TALZENNA Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions (5.1)]
Myelosuppression [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to single agent TALZENNA in solid tumor clinical studies, including 286 patients enrolled in EMBRACA trial and to TALZENNA 0.5 mg daily in combination with enzalutamide in 511 patients enrolled in the TALAPRO-2 trial that included 197 patients with HRR gene-mutated mCRPC.

gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer

EMBRACA

The safety of TALZENNA as a single agent was evaluated in gBRCAm patients with HER2-negative locally advanced or metastatic breast cancer who had previously received no more than 3 lines of chemotherapy for the treatment of locally advanced/metastatic disease [see Clinical Studies (14.1)]. EMBRACA was a randomized, open-label, multi-center study in which 412 patients received either TALZENNA 1 mg once daily (N=286) or a chemotherapy agent (capecitabine, eribulin, gemcitabine, or vinorelbine) of the healthcare provider's choice (N=126) until disease progression or unacceptable toxicity. The median duration of study treatment was 6.1 months in patients who received TALZENNA and 3.9 months in patients who received chemotherapy.

Serious adverse reactions of TALZENNA occurred in 32% of patients. Serious adverse reactions reported in >2% of patients included anemia (6%) and pyrexia (2%). Fatal adverse reactions occurred in 1% of patients, including cerebral hemorrhage, liver disorder, veno-occlusive liver disease, and worsening neurological symptoms (1 patient each).

Permanent discontinuation due to adverse reactions occurred in 5% of TALZENNA patients. Dosing interruptions due to an adverse reaction of any grade occurred in 65% of patients receiving TALZENNA; dose reductions due to any cause occurred in 53% of TALZENNA patients.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased, fatigue, glucose increased, aspartate aminotransferase increased, alkaline phosphatase increased, alanine aminotransferase increased, calcium decreased, nausea, headache, vomiting, alopecia, diarrhea, and decreased appetite.

Table 5 and Table 6 summarize the most common adverse reactions and laboratory abnormalities, respectively, in patients treated with TALZENNA or chemotherapy in the EMBRACA study.

Table 5. Adverse Reactions* (≥20%) in Patients Receiving TALZENNA in EMBRACA
Adverse ReactionsTALZENNA
N=286 (%)
Chemotherapy
N=126 (%)
Grades 1–4Grade 3Grade 4Grades 1–4Grade 3Grade 4
Abbreviation: N=number of patients.
*
Graded according to NCI CTCAE 4.03.
Includes fatigue and asthenia.

General disorders and administration site conditions

Fatigue

62

3

0

50

5

0

Gastrointestinal disorders

Nausea

49

0.3

0

47

2

0

Vomiting

25

2

0

23

2

0

Diarrhea

22

1

0

26

6

0

Nervous system disorders

Headache

33

2

0

22

1

0

Skin and subcutaneous tissue disorders

Alopecia

25

0

0

28

0

0

Metabolism and nutrition disorders

Decreased appetite

21

0.3

0

22

1

0

Clinically relevant adverse reactions in <20% of patients who received TALZENNA included abdominal pain (19%), dizziness (17%), dysgeusia (10%), dyspepsia (10%), stomatitis (8%), and febrile neutropenia (0.3%).

Table 6. Select Laboratory Abnormalities (≥25%) of Patients in EMBRACA
TALZENNA
N*=286 (%)
Chemotherapy
N*=126 (%)
ParameterGrades 1–4Grade 3Grade 4Grades 1–4Grade 3Grade 4
Abbreviation: N=number of patients.
*
This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.
This number represents non-fasting glucose.

Hemoglobin decreased

90

39

0

77

6

0

Neutrophils decreased

68

17

3

70

21

17

Lymphocytes decreased

76

17

0.7

53

8

0.8

Platelets decreased

55

11

4

29

2

0

Glucose increased

54

2

0

51

2

0

Aspartate aminotransferase Increased

37

2

0

48

3

0

Alkaline phosphatase increased

36

2

0

34

2

0

Alanine aminotransferase increased

33

1

0

37

2

0

Calcium decreased

28

1

0

16

0

0

HRR Gene-mutated mCRPC

The safety of TALZENNA in combination with enzalutamide was evaluated in patients with HRR gene-mutated mCRPC enrolled in TALAPRO-2 [see Clinical Studies (14.2)]. Patients were randomized to receive either TALZENNA 0.5 mg in combination with enzalutamide 160 mg once daily (n=197), or placebo in enzalutamide 160 mg once daily (n=199) until disease progression or unacceptable toxicity. Among patients receiving TALZENNA, 86% were exposed for 6 months or longer, 60% were exposed for greater than one year, and 18% were exposed for greater than two years.

Serious adverse reactions of TALZENNA in combination with enzalutamide occurred in 30% of patients. Serious adverse reactions reported in >2% of patients included anemia (9%) and fracture (3%). Fatal adverse reactions occurred in 1.5% of patients, including pneumonia, COVID infection, and sepsis (1 patient each).

Permanent discontinuation of TALZENNA due to adverse reactions occurred in 10% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in permanent discontinuation of TALZENNA were anemia (4%), fatigue, bone fracture, ischemic heart disease, and spinal cord compression (1% each).

Dosage interruption of TALZENNA due to adverse reactions occurred in 58% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose interruption of TALZENNA were anemia (42%), neutropenia (15%), and platelet count decreased (9%) and fatigue (5%).

Dose reduction of TALZENNA due to adverse reactions occurred in 52% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose reduction of TALZENNA were anemia (43%), neutrophil count decreased (15%), platelet count decreased (6%), and fatigue (4%).

The most common adverse reactions (≥10%), including laboratory abnormalities, in patients who received TALZENNA with enzalutamide were hemoglobin decreased, neutrophils decreased, lymphocytes decreased, fatigue, platelets decreased, calcium decreased, nausea, decreased appetite, sodium decreased, phosphate decreased, fractures, magnesium decreased, dizziness, bilirubin increased, potassium decreased, and dysgeusia.

Table 7 and Table 8 summarize the most common adverse reactions and laboratory abnormalities, respectively, in the TALAPRO-2 study.

Table 7. Adverse Reactions* (≥10%) in Patients Receiving TALZENNA [with a Difference Between Arms of ≥2%] in TALAPRO-2
Abbreviation: N=number of patients.
*
Graded according to NCI CTCAE 4.03.
Includes fatigue and asthenia.
Fractures include multiple similar terms.
§
Includes dizziness, dizziness postural, vertigo.
Includes ageusia, anosmia, dysgeusia.

TALZENNA with Enzalutamide

N=197

Placebo with Enzalutamide

N=199

Grades 1-4

%

Grade 3

%

Grade 4

%

Grades 1-4

%

Grade 3

%

Grade 4

%

Fatigue

49

4

0

40

1

0

Nausea

21

2

0

17

1

0.5

Decreased appetite

20

1

0

14

1

1

Fractures

14

3

0

10

1.5

0

Dizziness§

13

1.5

0

9

1.5

0

Dysgeusia

10

0

0

4.5

0

0

Clinically relevant adverse reactions in <10% of patients who received TALZENNA with enzalutamide included abdominal pain (9%), vomiting (9%), alopecia (7%), dyspepsia (4%), venous thromboembolism (3%) and stomatitis (2%).

Table 8. Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received TALZENNA in TALAPRO-2
Abbreviation: N=number of patients.
*
The denominator used to calculate the rate varied from 198 to 199 in the placebo with enzalutamide arm based on the number of patients with a baseline value and at least one post-treatment value.

Laboratory Abnormality

TALZENNA with Enzalutamide

N=197*

Placebo with Enzalutamide

N=199*

Grades 1‑4

%

Grade 3

%

Grade 4

%

Grades 1‑4

%

Grade 3

%

Grade 4

%

Hemoglobin decreased

79

41

0

34

6

0

Neutrophils decreased

60

18

1

18

0

1

Lymphocytes decreased

58

13

0

36

7

0

Platelets decreased

45

6

3

8

0.5

0

Calcium decreased

25

0

1

11

0

1

Sodium decreased

22

3

0

20

1.5

0

Phosphate decreased

17

3

1

13

2

0

Magnesium decreased

14

0

1

12

0

0.5

Bilirubin increased

11

0.5

0

7

0

0

Potassium decreased

11

0

1

7

1

0.5

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.